Sonnet S. Davis, Phd is a Scientist in Development Sciences with Denali Therapeutics. Based in San Francisco, Denali is dedicated to developing breakthrough therapies for neurodegenerative diseases through our deep commitment to degeneration biology and principles of translational medicine. In this position, Sonnet develops analytical technologies and strategies for (1) disease-based biomarker development and (2) mechanistic studies for emerging neurodegeneration“degenogene” targets. She is also an active member of Denalis’ STEM outreach program, an initiative that supports community engagement through educational projects.
Sonnet received her BS in Biochemistry from Oakwood University and her PhD in Analytical Chemistry from the University of Maryland Baltimore County (UMBC).